Literature DB >> 14616868

Effect of FK506 eye drops on late and delayed-type responses in ocular allergy models.

T Sengoku1, S Sakuma, S Satoh, S Kishi, T Ogawa, Y Ohkubo, S Mutoh.   

Abstract

BACKGROUND: It is well-known that FK506 strongly inhibits cytokine production by T cells in vitro. However, less evidence is available from in vivo studies of ocular allergy.
OBJECTIVE: To study the anti-inflammatory effect of FK506 eye drops on late and delayed-type responses in several animal models of ocular allergy.
METHODS: Rats and guinea-pigs were sensitized with egg albumin (EA) in adjuvant and later challenged by topical EA application to their eyes to examine the late response. Biopsy specimens of conjunctiva were stained with haematoxylin-eosin or stained for T cells and eosinophils. In addition, rats, rabbits and guinea-pigs were sensitized with complete Freund's adjuvant and later challenged by injecting purified protein derivatives for the delayed-type response. Bulbar conjunctival oedema and hyperaemia were graded by score in rabbits, and Evans blue (EB) extravasation was measured in rats and guinea-pigs. FK506 (0.01-1%) and steroid (0.1%) eye drops were instilled in the eyes of animals several times, before and after challenge.
RESULTS: FK506 eye drops inhibited T cell and eosinophil infiltration in the late response and EB extravasation in the delayed-type response in rats. Also, they inhibited conjunctival oedema, hyperaemia and ocular mucus in the delayed-type response in rabbits. These effects were similar to those of steroid eye drops (betamethasone sodium phosphate, fluorometholone). FK506 eye drops also inhibited inflammatory cell infiltration, the loss of conjunctival epithelium and decrease of goblet cells in the late response as well as EB extravasation in the delayed-type response in guineapigs, a steroid-resistant species.
CONCLUSION: FK506 eye drops inhibit late and delayed-type responses in animal models of ocular allergy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616868     DOI: 10.1046/j.1365-2222.2003.01698.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  4 in total

1.  Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis.

Authors:  A Kheirkhah; M K Zavareh; F Farzbod; M Mahbod; M J Behrouz
Journal:  Eye (Lond)       Date:  2011-04-08       Impact factor: 3.775

2.  Eosinophil cationic protein as a marker for assessing the efficacy of tacrolimus ophthalmic solution in the treatment of atopic keratoconjunctivitis.

Authors:  Tais Hitomi Wakamatsu; Mari Tanaka; Yoshiyuki Satake; Murat Dogru; Kazumi Fukagawa; Ayako Igarashi; Hiroshi Fujishima
Journal:  Mol Vis       Date:  2011-04-13       Impact factor: 2.367

Review 3.  Ocular redness - II: Progress in development of therapeutics for the management of conjunctival hyperemia.

Authors:  Rohan Bir Singh; Lingjia Liu; Ann Yung; Sonia Anchouche; Sharad K Mittal; Tomas Blanco; Thomas H Dohlman; Jia Yin; Reza Dana
Journal:  Ocul Surf       Date:  2021-05-15       Impact factor: 6.268

4.  Tacrolimus Ointment for Treatment of Vernal Keratoconjunctivitis.

Authors:  Abdulrahman M Al-Amri; Aleem Gulzar Mirza; Ahmed Mossa Al-Hakami
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.